Armand Van Deun

Geneeskundige en Gezondheidsdienst — Netherlands

Medicine · Health Sciences

42h-index7.9kcitations185works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(163), Mycobacterium research and diagnosis(77), Pneumonia and Respiratory Infections(44), Pneumocystis jirovecii pneumonia detection and treatment(41), Diagnosis and treatment of tuberculosis(23)

Publications184 total

Prevalence of non-tuberculous mycobacteria among people with acid-fast positive presumptive tuberculosis in Mali
PLoS ONE·2024· 1 citedOpen Access
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial
The Lancet Respiratory Medicine·2024· 10 citedOpen Access
Safety of high-dose amikacin in the first week of all-oral rifampicin-resistant tuberculosis treatment for the prevention of acquired resistance (STAKE): protocol for a single-arm clinical trial
BMJ Open·2024Open Access
Prevalence of non-tuberculous mycobacteria among people presumed to have tuberculosis, positive for acid-fast bacilli in Mali
2024Open Access
Borderline rpoB mutations transmit at the same rate as common rpoB mutations in a tuberculosis cohort in Bangladesh
Microbial Genomics·2023· 3 citedOpen Access
GeneXpert MTB/RIF Ultra performance to detect uncommon rpoB mutations in Mycobacterium tuberculosis
BMC Research Notes·2023· 4 citedOpen Access
High rate of adverse drug reactions with a novel tuberculosis re-treatment regimen combining triple doses of both isoniazid and rifampicin
International Journal of Infectious Diseases·2023· 11 citedOpen Access
Borderline <i>rpoB</i> mutations transmit at the same rate as common <i>rpoB</i> mutations in a tuberculosis cohort in Bangladesh
2023Open Access
Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation
Trials·2022· 7 citedOpen Access
GeneXpert Ultra performance to detect uncommon rpoB mutations in Mycobacterium tuberculosis
Research Square (Research Square)·2022Open Access
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
The Lancet·2022· 134 citedOpen Access
Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB
The International Journal of Tuberculosis and Lung Disease·2022· 4 citedOpen Access
Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis
Trials·2022· 8 citedOpen Access
Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings
JAC-Antimicrobial Resistance·2022· 8 citedOpen Access
Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study
International Health·2022· 5 citedOpen Access
Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review
JAC-Antimicrobial Resistance·2022· 71 citedOpen Access
Effectiveness of GenoType MTBDR <i>sl</i> in excluding TB drug resistance in a clinical trial
The International Journal of Tuberculosis and Lung Disease·2021· 3 citedOpen Access
Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
European Respiratory Journal·2021· 4 citedOpen Access
Pretomanid for tuberculosis: a systematic review
Clinical Microbiology and Infection·2021· 71 citedOpen Access
<i>Mycobacterium tuberculosis</i>borderline<i>rpoB</i>mutations: emerging from the unknown
European Respiratory Journal·2021· 22 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Leen Rigouts(15), Bouke C. de Jong(12), Françoise Portaels(8), A Wright(7), Gabriela Torrea(7), Tom Decroo(7), Alberto Piubello(6), Mourad Gumusboga(6), Matteo Zignol(5), Chen‐Yuan Chiang(5), I. D. Rusen(5), K. J. M. Aung(5), Arnaud Trébucq(5), K. Fissette(5), Dennis Falzon(4), Hans L. Rieder(4), Willem Bram de Rijk(4), Conor J. Meehan(4), Hans L. Rieder(3), Francis Drobniewski(3)